Related Experiment Video

Updated: Jun 2, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies

Erinn Downs-Kelly1, Brian P Rubin

  • 1Departments of Anatomic and Molecular Pathology, Cleveland Clinic, 9500 Euclid Avenue, L25, Cleveland, OH 44195, USA.

Pathology Research International
|May 12, 2011
PubMed

Insights

Gastrointestinal stromal tumors (GISTs) are common but resistant to traditional treatments. Targeted therapies, specifically tyrosine kinase inhibitors, are effective due to common KIT or PDGFRA mutations driving GIST development.

Area of Science:

  • Gastrointestinal Oncology
  • Molecular Pathology
  • Cancer Therapeutics

Background:

  • Gastrointestinal stromal tumors (GISTs) represent the most frequent mesenchymal neoplasms within the GI tract.
  • GISTs exhibit significant heterogeneity in clinical behavior and histological presentation.
  • Conventional chemotherapy and radiation demonstrate limited efficacy against GISTs.

Purpose of the Study:

  • To review the clinicopathological characteristics of GIST.
  • To explore the clinical and therapeutic implications of specific genetic mutations in GIST.
  • To highlight the role of tyrosine kinase inhibitors in GIST treatment.

Main Methods:

  • Literature review focusing on GIST clinicopathology.
  • Analysis of studies investigating KIT and PDGFRA mutations in GIST.
  • Examination of treatment outcomes with tyrosine kinase inhibitors.

Main Results:

  • GISTs are characterized by specific mutations in KIT or PDGFRA in 85-90% of cases, driving tumor formation.
  • These mutations confer sensitivity to small-molecule tyrosine kinase inhibitors.
  • GISTs are largely unresponsive to conventional sarcoma therapies.

Conclusions:

  • KIT and PDGFRA mutations are pivotal in GIST pathogenesis and treatment response.
  • Tyrosine kinase inhibitors represent a primary therapeutic strategy for GIST.
  • Understanding these mutations is crucial for effective GIST management.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...